Westpac Banking Corp Purchases Shares of 1,475 United Therapeutics Corporation $UTHR

Westpac Banking Corp acquired a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,475 shares of the biotechnology company’s stock, valued at approximately $719,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in UTHR. Optimize Financial Inc acquired a new stake in shares of United Therapeutics in the third quarter worth $444,000. Leuthold Group LLC lifted its position in United Therapeutics by 41.4% in the fourth quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after purchasing an additional 3,126 shares during the period. Tobam lifted its position in United Therapeutics by 183.9% in the third quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock worth $3,205,000 after purchasing an additional 4,953 shares during the period. UBS Group AG lifted its position in United Therapeutics by 45.3% in the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after purchasing an additional 70,445 shares during the period. Finally, Perpetual Ltd bought a new position in United Therapeutics in the fourth quarter worth $1,059,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on UTHR shares. Royal Bank Of Canada reduced their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. UBS Group boosted their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Cantor Fitzgerald lifted their price target on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

Insider Buying and Selling

In related news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $547.87, for a total value of $5,478,700.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,341,594.12. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $562.82, for a total value of $4,671,406.00. Following the completion of the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $25,423,705.04. The trade was a 15.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 605,743 shares of company stock worth $340,981,769 over the last three months. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Stock Up 1.7%

Shares of UTHR stock opened at $549.47 on Thursday. The stock has a 50-day moving average price of $567.74 and a 200 day moving average price of $518.04. The firm has a market cap of $23.33 billion, a price-to-earnings ratio of 20.28, a PEG ratio of 1.75 and a beta of 0.57. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.63 earnings per share. Sell-side analysts predict that United Therapeutics Corporation will post 26.92 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.